Claims
- 1. A biocompatible device, comprising:
(a) a polymeric base; and (b) a surface layer coating said polymeric base, said surface layer comprising a polyether or polyether/carbonate based urethane polymer prepared by a method comprising the steps of:
(i) forming a diisocyanate terminated prepolymer based on (i) a polyether glycol or polyether/cabonate glycol having a molecular weight between about 200 to 3,000 Da and (ii) a diisocyanate having the general structure OCN—R′—NCO, wherein R′ is a hydrocabon; and (ii) chain extending said prepolymer using a dihydroxy carboxylic acid.
- 2. The device of claim 1, wherein said device is a vascular graft comprising a graft wall base and a surface layer coating the inner or outer surface of said graft wall base.
- 3. The device of claim 2, wherein said graft wall comprises a polymeric material selected from the group consisting of polyethylene terephthalate, polyurethane, polyethylene, polypropylene, silicons, and nylon.
- 4. The device of claim 3, wherein said graft is a knitted polyethylene terephthalate double velour vascular graft.
- 5. The device of claim 2, wherein proteins are covalently attached to said surface layer.
- 6. The device of claim 5, wherein said proteins are selected from the group consisting of anti-clotting agents, thrombolytic agents, mitogenic agents, growth promoting substances, and inhibitors.
- 7. The device of claim 6, wherein said proteins comprise vascular endothelial growth factor (VEGF) and recombinant hirudin (rHir).
- 8. The device of claim 1, wherein said diisocyanate is selected from the group consisting of 4,4′-diphenylmethane diisocyanate (MDI), hydrogenated methylene diisocyanate (HMDI), hexamethylene diisocyanate, toluene diisocyanates, 4,4′-tolidine diisocyanate, m-phenylene diisocyanate, 4-chloro-1,3-phenylene diisocyanate, 4,4-tetramethylene diisocyante, 1,6-hexamethylene diisocyanate, 1,10-decamethylene diisocyanate, 1,4-cyclohexylene diisocyanate, 4,4′-methylene bis (cyclo hexylisocyanate), 1,4-isophorone diisocyanate, 3,3′-dimethyl-4,4′-diphenylmethane diisocyanate, and 1,5-tetrahydronaphthalene diisocyanate.
- 9. The device of claim 8, wherein said diisocyanate is 4,4′-diphenylmethane diisocyanate (MDI).
- 10. The device of claim 1, wherein said polyether glycol is polytetramethylene ether glycol (PTMEG1000).
- 11. The device of claim 1, wherein said polyether/carbonate glycol is polyetherpolycarbonatediol.
- 12. The device of claim 1, wherein said carboxylic acid is 2,2-bis(hydroxymethyl)-propionic acid (DHMPA).
- 13. The device of claim 1, wherein said molecular weight is about 1,000 Da.
- 14. The device of claim 2, wherein said graft has a vascular shape with an internal diameter between about 2.0 and 20.0 mm.
- 15. The device of claim 2, wherein said graft has a vascular shape with an internal diameter less than about 9.0 mm.
- 16. The device of claim 15, wherein said graft has a vascular shape with an internal diameter less than about 6.0 mm.
- 17. The device of claim 16, wherein said graft has a vascular shape with an internal diameter less than about 5.0 mm.
- 18. The device of claim 14, wherein said graft has a vascular shape with an internal diameter between 6.0 and 8.0 mm.
Parent Case Info
[0001] This application claims priority from U.S. Ser. No. 60/186,154, which was filed on Feb. 29, 2000.
STATEMENT OF FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under a grant entitled DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT/1R41HL63511-01A1 awarded by the National Heart, Lung, and Blood Institute through a Small Business Technology Transfer Research Program. The government has certain rights to the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60186154 |
Feb 2000 |
US |